Amalgamated Financial’s Pacira BioSciences PCRX Stock Holding History

Amalgamated Financial’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$1.67M	Buy	+21,890	New	+$1.46M	0.01%	974

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Amalgamated Financial's PCRX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Pacira BioSciences (PCRX) in Q1 2022: 21,890 shares worth $1.67M. The stake represents 0.01% of the portfolio and ranks #974 among its holdings.

301 funds tracked by Wall St. Rank hold PCRX as of Q1 2022.

Amalgamated Financial held 21,890 shares of Pacira BioSciences worth $1.67M as of Q1 2022.
Pacira BioSciences was a new Amalgamated Financial position in Q1 2022.
Pacira BioSciences made up 0.01% of Amalgamated Financial's portfolio in Q1 2022, its #974 holding.
301 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.